CanSino Biologics Inc
688185
Company Profile
Business description
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.
Contact
185 South Avenue
401-420, 4th Floor, Biomedical Park
TEDA West District
Tianjin
CHNT: +86 4009222099
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,105
Stocks News & Analysis
stocks
Looking for growth outside the ASX100
Small caps have outperformed blue chips this year. Here’s some opportunities outside the ASX100.
stocks
Netflix and Warner Bros. Discovery: Surprisingly high merger price alters shareholder value for both
Our view on the blockbuster merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,898.00 | 9.10 | 0.10% |
| CAC 40 | 8,114.74 | 7.29 | -0.09% |
| DAX 40 | 24,028.14 | 146.11 | 0.61% |
| Dow JONES (US) | 47,954.99 | 104.05 | 0.22% |
| FTSE 100 | 9,667.01 | 43.86 | -0.45% |
| HKSE | 25,986.82 | 98.26 | -0.38% |
| NASDAQ | 23,578.13 | 72.99 | 0.31% |
| Nikkei 225 | 50,395.14 | 96.73 | -0.19% |
| NZX 50 Index | 13,526.19 | 42.20 | 0.31% |
| S&P 500 | 6,870.40 | 13.28 | 0.19% |
| S&P/ASX 200 | 8,608.00 | 12.40 | 0.14% |
| SSE Composite Index | 3,908.25 | 5.45 | 0.14% |